Moran Susan — SEC Form 4 filings
SEC reporting owner CIK 1835225. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-03.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-02-06 to 2026-06-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| RayzeBio, Inc. (RYZB) | CHIEF MEDICAL OFFICER | 2 | — | — | 7 |
| Tyra Biosciences, Inc. (TYRA) | Director | 3 | — | — | 3 |
| BioAtla, Inc. (BCAB) | Director | 2 | — | — | 2 |
| CRESCENT BIOPHARMA, INC. (CBIO) | Director | 2 | — | — | 2 |
Form 4 filings — Moran Susan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-03 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 13,160 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | GLYCOMIMETICS INC (CBIO) | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | BioAtla, Inc. (BCAB) | Grant/award (A): 23,500 @ $0 | EDGAR |
| 2025-06-02 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 22,200 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | BioAtla, Inc. (BCAB) | Grant/award (A): 16,500 @ $0 | EDGAR |
| 2024-05-09 | 4 | Tyra Biosciences, Inc. (TYRA) | Grant/award (A): 37,200 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | RayzeBio, Inc. (RYZB) | Disposition to issuer (D): 323,455 @ $62.50 · Disposition to issuer (D): 60,757 (derivative) · Disposition to issuer (D): 77,805 (derivative) · Disposition to issuer (D): 194,514 (derivative) · Disposition to issuer (D): 164,000 (derivative) | EDGAR |
| 2024-02-06 | 4 | RayzeBio, Inc. (RYZB) | Option exercise (M): 30,875 @ $3.24 · Option exercise (M): 30,875 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1835225 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →